Recombinant human tumor necrosis factor administered as a five-day continuous infusion in cancer patients: phase I toxicity and effects on lipid metabolism.
about
Bystander target cell lysis and cytokine production by dengue virus-specific human CD4(+) cytotoxic T-lymphocyte clonesThe role of inflammation in cholestasis: clinical and basic aspectsAmyloid β: one of three danger-associated molecules that are secondary inducers of the proinflammatory cytokines that mediate Alzheimer's diseaseAttenuation of soft-tissue sarcomas resistance to the cytotoxic action of TNF-α by restoring p53 functionNuclear receptors: mediators and modifiers of inflammation-induced cholestasis.The meteorology of cytokine storms, and the clinical usefulness of this knowledgePerispinal etanercept for post-stroke neurological and cognitive dysfunction: scientific rationale and current evidenceSequential cancer immunotherapy: targeted activity of dimeric TNF and IL-8.Agents that increase AAM differentiation blunt RSV-mediated lung pathology.Maternal death following cardiopulmonary collapse after delivery: amniotic fluid embolism or septic shock due to intrauterine infection?Selective protection of human liver tissue in TNF-targeting of cancers of the liver by transient depletion of adenosine triphosphate.Neonatal sepsis and inflammatory mediators.Development of a novel DDS for site-specific PEGylated proteins.Ameliorative effect of allopurinol on vascular complications of insulin resistanceSystemic use of tumor necrosis factor alpha as an anticancer agentFructose protects murine hepatocytes from tumor necrosis factor-induced apoptosis by modulating JNK signaling.ApoM Suppresses TNF-α-Induced Expression of ICAM-1 and VCAM-1 Through Inhibiting the Activity of NF-κBHumoral mediation for cachexia in tumour-bearing rats.Metabolic effects of tumour necrosis factor alpha in NMRI miceDecrease in cholesterol levels during the immunotherapy of cancer with interleukin-2.Modulation of lipoprotein plasma concentrations during long-term anti-TNF therapy in patients with active rheumatoid arthritis.Circadian dynamics of tumor necrosis factor alpha (cachectin) lethality.Basophils are the major producers of IL-4 during primary helminth infection.Role of prostaglandins in tumour necrosis factor induced weight lossPotentiation of ionising radiation by targeting tumour necrosis factor alpha using a bispecific antibody in human pancreatic cancer.Cytokines in sepsis: potent immunoregulators and potential therapeutic targets--an updated view.Combination of Gold Nanoparticle-Conjugated Tumor Necrosis Factor-α and Radiation Therapy Results in a Synergistic Antitumor Response in Murine Carcinoma Models.Lack of protection against bacterial infections in patients with advanced cancer treated by biologic response modifiersImmune-to-brain signaling: how important are the blood-brain barrier-independent pathways?Tumour necrosis factor: a cytokine with multiple biological activities.Metabolic syndrome and chronic arthritis: effects of anti-TNF-α therapy.Cardiovascular risk in patients with rheumatoid arthritis.Linkage with cathepsin B-sensitive dipeptide promotes the in vitro and in vivo anticancer activity of PEGylated tumor necrosis factor-alpha (TNF-α) against murine fibrosarcoma.A phase IIa study of rhLTα-Da in combination with cisplatin and fluorouracil for patients with metastatic esophageal squamous cell carcinoma or gastric adenocarcinoma.An investigation of adverse effects caused by the injection of high-dose TNFalpha-expressing adenovirus vector into established murine melanoma.Gene delivery from the E3 region of replicating human adenovirus: evaluation of the 6.7 K/gp19 K region.Effects of recombinant monokines on hepatic pyruvate dehydrogenase, pyruvate dehydrogenase kinase, lipogenesis de novo and plasma triacylglycerols. Abolition by prior fasting.Tumour necrosis factor, cholestatic jaundice, and chronic liver diseaseGene delivery from the E3 region of replicating human adenovirus: evaluation of the ADP region.Tumor-targeted gene delivery of tumor necrosis factor-alpha induces tumor necrosis and tumor regression without systemic toxicity.
P2860
Q27469356-C7F1A952-D78E-45B5-8745-F623C0E17EDCQ27694662-E688424A-89E0-4909-994F-5BEEC8F36243Q28384947-F8A91B14-FF11-4F88-9ADD-C88A3F2E0B2EQ28728301-DDCA16D2-D56C-4960-B0D0-7D3C82BD9B45Q33859400-28788FF8-11BE-4B55-AA5F-03B3004F51C3Q33867213-62E546E8-07C2-49A0-AD66-E7467AA54477Q33947639-E3D03FF1-A201-4E96-979F-E788DD5227C0Q34111796-12AA8866-A84D-417F-8200-1758517CB0DBQ34484085-E3745583-BD16-49B6-B9EF-2C36ABAEA6B6Q34494722-DD495FFD-4AFA-41FB-A73F-58C40579DD7FQ34526187-3A7C625B-6027-4EFE-B674-1AA684957949Q34970523-3372253E-B05C-420D-A27F-F15D420B17ACQ35040200-4453BF37-5761-4C61-8549-087646FC8742Q35133164-69708025-844D-46DB-B8B0-1E33D24AEF4FQ35640180-FEF5D41F-303B-42ED-B45C-8ED43AC3A5DEQ35693976-EA1CBE11-AE90-46BD-997E-7BF31E2747EAQ35910652-5E8BAF8E-4AB7-4E9B-BFA7-9EB3FAA2134BQ35975846-E155EF24-3C9B-4834-B68C-06552CFF3AF8Q35981614-4A0FAD29-C4C9-4975-9B5B-A9FDF0B27605Q35993345-2CABB76E-0CE8-4CD2-8014-4CD9DA1E7380Q36204149-01C14974-A465-4F9D-B20A-00C66F727377Q36363709-515DAF78-50EB-4967-B7A7-F2B5ECCBA433Q36370697-474E7C8D-32AC-45A3-AF24-CAEF23506C9CQ36468091-33C89D47-13E6-4C5A-9501-30DDDD20E13DQ36671593-ECF84236-CC2E-4BB0-B212-AC5197680EA3Q36990515-DB71E200-DCBB-41A2-A602-266D93CBE41AQ37068894-D1523E9B-2F21-4E01-871E-97E8A11CB380Q37160892-564A3C6C-7830-47C9-8919-6909076DA5C3Q37194695-ABEFC164-C8A0-42CD-85B5-71AF99F9A6FDQ37916679-E5C89171-DC9B-4D2A-8D38-391BF68DEA65Q38271745-251464E6-A72D-4297-9B7A-580558A6B7BDQ38813397-82769C11-1105-4FDA-9945-72E50B7C2716Q39592845-212FCD0E-BB69-4087-9212-F03D939D0600Q40085069-DB86BCBC-2474-4574-9830-FA5C5C209EAAQ40594323-78FB8F56-F488-4E76-8481-A56BB7F9677CQ40785400-EA0ECB55-16B5-4FC7-AADE-56852ACAF57BQ41983757-114895A1-9716-4DDA-99D1-48B410F2B3BCQ42087829-AEC15903-A424-4DF3-B660-4697154B8FF8Q43710400-D3F7B92F-18E5-4824-B08E-E4CB82AFD077Q45888026-7E538727-E336-48A6-A063-F7D005FDAFC5
P2860
Recombinant human tumor necrosis factor administered as a five-day continuous infusion in cancer patients: phase I toxicity and effects on lipid metabolism.
description
1988 nî lūn-bûn
@nan
1988 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
1988 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
1988年の論文
@ja
1988年論文
@yue
1988年論文
@zh-hant
1988年論文
@zh-hk
1988年論文
@zh-mo
1988年論文
@zh-tw
1988年论文
@wuu
name
Recombinant human tumor necros ...... d effects on lipid metabolism.
@ast
Recombinant human tumor necros ...... d effects on lipid metabolism.
@en
type
label
Recombinant human tumor necros ...... d effects on lipid metabolism.
@ast
Recombinant human tumor necros ...... d effects on lipid metabolism.
@en
prefLabel
Recombinant human tumor necros ...... d effects on lipid metabolism.
@ast
Recombinant human tumor necros ...... d effects on lipid metabolism.
@en
P2093
P356
P1476
Recombinant human tumor necros ...... d effects on lipid metabolism.
@en
P2093
P304
P356
10.1200/JCO.1988.6.2.344
P407
P577
1988-02-01T00:00:00Z